This is a Validated Antibody Database (VAD) review about Rhesus mon.. CD28, based on 38 published articles (read how Labome selects the articles), using CD28 antibody in all methods. It is aimed to help Labome visitors find the most suited CD28 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
CD28 synonym: T-cell-specific surface glycoprotein CD28; CD28 precursor protein

BioLegend
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig 1a
BioLegend CD28 antibody (Biolegend, CD28.2) was used in blocking or activating experiments on human samples (fig 1a). Eur J Immunol (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig s2e
BioLegend CD28 antibody (BioLegend, 302920) was used in flow cytometry on human samples (fig s2e). Cell (2018) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 5c
BioLegend CD28 antibody (Biolegend, 28.2) was used in flow cytometry on human samples (fig 5c). J Immunol (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 2c
BioLegend CD28 antibody (Biolegend, 28.2) was used in flow cytometry on human samples (fig 2c). Sci Rep (2017) ncbi
mouse monoclonal (CD28.2)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, BioLegend CD28 antibody (BioLegend, CD28.2) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig 2c
BioLegend CD28 antibody (Biolegend, CD28.2) was used in blocking or activating experiments on human samples (fig 2c). Oncotarget (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
In order to find a role for IL-4 in promoting breast cancer aggressiveness, BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples . Cancer Res (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig s1e
In order to use CD49a expression to define subsets of tissue-resident memory T cells in the skin, BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig s1e). Immunity (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; Rhesus monkey; loading ...; fig 4b
In order to study CXCR5+ CD8 T cells in SIV-infected animals, BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on Rhesus monkey samples (fig 4b). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig s6b
In order to assess whether human T-cell leukemia virus type 1 bZIP factor enhances the proliferation of expressing T cells after stimulation via the T-cell receptor, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on human samples (fig s6b). PLoS Pathog (2017) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 1b
In order to characterize gammadelta T cell subsets from healthy humans, BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig 1b). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 6a
In order to study the role of PD-1 and Tim-3 crosstalk in the regulation of antitumor T cell responses, BioLegend CD28 antibody (Biolegend, 302914) was used in flow cytometry on human samples (fig 6a). Oncoimmunology (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...; fig s4a
In order to study the contribution of T follicular helper cells to islet autoimmunity, BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples (fig s4a). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; Rhesus monkey; fig 4a
In order to examine the contribution of HIV-derived conserved elements in vaccination, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on Rhesus monkey samples (fig 4a). J Immunol (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; 10 ng/ml
BioLegend CD28 antibody (Biolegend, 302913) was used in blocking or activating experiments on human samples at 10 ng/ml. Respir Res (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...
BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig s1
BioLegend CD28 antibody (Biolegend, 28.2) was used in flow cytometry on human samples (fig s1). PLoS Pathog (2016) ncbi
mouse monoclonal (CD28.2)
  • ELISA; human; 2.5 ug/ml; loading ...
In order to find that internal membrane reservoirs in T lymphocytes are recruited, likely through exocytosis, to induce large active deformations, BioLegend CD28 antibody (Biolegend, BLE302923) was used in ELISA on human samples at 2.5 ug/ml. Mol Biol Cell (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 2b
In order to suggest that the BRD4-p300 signaling cascade promotes antitumor T cell grafts that could be used adoptive immunotherapy, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on human samples (fig 2b). J Clin Invest (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 4
BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig 4). J Immunol Res (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; loading ...
In order to generate a T-cell receptor-like monoclonal antibody (8F4) that binds the PR1/HLA-A2 complex and test it in preclinical models of acute myeloid leukemia, BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . Cytotherapy (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 1
BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples (fig 1). Sci Rep (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 5 ug/ml; loading ...; fig s2
BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on human samples at 5 ug/ml (fig s2). Anesthesiology (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 2
BioLegend CD28 antibody (BioLegend, 302925) was used in flow cytometry on human samples (fig 2). Nat Biotechnol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; loading ...; fig 1a
In order to characterize innate lymphoid cell subpopulations isolated from patients with systemic sclerosis, BioLegend CD28 antibody (biolegend, CD28.2) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 3
BioLegend CD28 antibody (BioLegend, 28.2) was used in blocking or activating experiments on human samples (fig 3). J Immunol Methods (2016) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
In order to present the role of M-sec in polarized secretion of inflammatory endothelial chemokines and CCL2-mediated lymphocyte transendothelial migration, BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . J Leukoc Biol (2016) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 1
In order to assess the CD4/CD8 ratio as a marker for CD4+ T cell dysfunction in chronic HIV infection, BioLegend CD28 antibody (Biolegend, clone CD28.2) was used in flow cytometry on human samples (fig 1). PLoS ONE (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human
BioLegend CD28 antibody (Biolegend, 302906) was used in flow cytometry on human samples . Cytometry A (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 7
BioLegend CD28 antibody (Biolegend, CD28.2) was used in blocking or activating experiments on human samples (fig 7). Nat Commun (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; tbl 2
BioLegend CD28 antibody (BioLegend, 302934) was used in blocking or activating experiments on human samples (tbl 2). Immunol Lett (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human; fig 6
BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples (fig 6). Cancer Res (2015) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . Cell Signal (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; fig 3
In order to compare five SIV vaccine platforms, BioLegend CD28 antibody (BioLegend, clone CD28.2) was used in flow cytometry on human samples (fig 3). Clin Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • blocking or activating experiments; human
BioLegend CD28 antibody (BioLegend, CD28.2) was used in blocking or activating experiments on human samples . Arch Immunol Ther Exp (Warsz) (2015) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; Rhesus monkey
In order to examine the effect of HMBPP-deficient Listeria mutant immunization, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on Rhesus monkey samples . J Leukoc Biol (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; human; 1 ug/ml
BioLegend CD28 antibody (Biolegend, CD28.2) was used in flow cytometry on human samples at 1 ug/ml. Med Microbiol Immunol (2014) ncbi
mouse monoclonal (CD28.2)
  • flow cytometry; Rhesus monkey
In order to compare vaccination with highly conserved gag elements verses full-length gag DNA, BioLegend CD28 antibody (BioLegend, CD28.2) was used in flow cytometry on Rhesus monkey samples . PLoS ONE (2014) ncbi
Articles Reviewed
  1. Fischer M, Bantug G, Dimeloe S, Gubser P, Burgener A, Grählert J, et al. Early effector maturation of naïve human CD8+ T cells requires mitochondrial biogenesis. Eur J Immunol. 2018;: pubmed publisher
  2. Gee M, Han A, Lofgren S, Beausang J, Mendoza J, Birnbaum M, et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell. 2018;172:549-563.e16 pubmed publisher
  3. Salio M, Gasser O, González López C, Martens A, Veerapen N, Gileadi U, et al. Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. J Immunol. 2017;199:2631-2638 pubmed publisher
  4. Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin M, Harper L, et al. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Sci Rep. 2017;7:7652 pubmed publisher
  5. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  6. Domae E, Hirai Y, Ikeo T, Goda S, Shimizu Y. Cytokine-mediated activation of human ex vivo-expanded V?9V?2 T cells. Oncotarget. 2017;8:45928-45942 pubmed publisher
  7. Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, et al. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. Cancer Res. 2017;77:3268-3279 pubmed publisher
  8. Cheuk S, Schlums H, Gallais Sérézal I, Martini E, Chiang S, Marquardt N, et al. CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin. Immunity. 2017;46:287-300 pubmed publisher
  9. Mylvaganam G, Rios D, Abdelaal H, Iyer S, Tharp G, Mavigner M, et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. Proc Natl Acad Sci U S A. 2017;114:1976-1981 pubmed publisher
  10. Kinosada H, Yasunaga J, Shimura K, Miyazato P, Onishi C, Iyoda T, et al. HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathog. 2017;13:e1006120 pubmed publisher
  11. Ryan P, Sumaria N, Holland C, Bradford C, Izotova N, Grandjean C, et al. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc Natl Acad Sci U S A. 2016;113:14378-14383 pubmed
  12. Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
  13. Serr I, Fürst R, Ott V, Scherm M, Nikolaev A, Gökmen F, et al. miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. Proc Natl Acad Sci U S A. 2016;113:E6659-E6668 pubmed
  14. Hu X, Valentin A, Dayton F, Kulkarni V, Alicea C, Rosati M, et al. DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV. J Immunol. 2016;197:3999-4013 pubmed
  15. Southworth T, Plumb J, Gupta V, Pearson J, Ramis I, Lehner M, et al. Anti-inflammatory potential of PI3K? and JAK inhibitors in asthma patients. Respir Res. 2016;17:124 pubmed
  16. Jung Y, Riven I, Feigelson S, Kartvelishvily E, Tohya K, Miyasaka M, et al. Three-dimensional localization of T-cell receptors in relation to microvilli using a combination of superresolution microscopies. Proc Natl Acad Sci U S A. 2016;113:E5916-E5924 pubmed
  17. Pachnio A, Ciáurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016;12:e1005832 pubmed publisher
  18. Guillou L, Babataheri A, Saitakis M, Bohineust A, Dogniaux S, Hivroz C, et al. T-lymphocyte passive deformation is controlled by unfolding of membrane surface reservoirs. Mol Biol Cell. 2016;27:3574-3582 pubmed
  19. Kagoya Y, Nakatsugawa M, Yamashita Y, Ochi T, Guo T, Anczurowski M, et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016;126:3479-94 pubmed publisher
  20. Heath J, Newhook N, Comeau E, Gallant M, Fudge N, Grant M. NKG2C(+)CD57(+) Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8(+) T Cell Evolution towards Senescence. J Immunol Res. 2016;2016:7470124 pubmed publisher
  21. Ma Q, Garber H, Lu S, He H, Tallis E, Ding X, et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016;18:985-94 pubmed publisher
  22. van der Heiden M, van Zelm M, Bartol S, de Rond L, Berbers G, Boots A, et al. Differential effects of Cytomegalovirus carriage on the immune phenotype of middle-aged males and females. Sci Rep. 2016;6:26892 pubmed publisher
  23. van der Heide V, Möhnle P, Rink J, Briegel J, Kreth S. Down-regulation of MicroRNA-31 in CD4+ T Cells Contributes to Immunosuppression in Human Sepsis by Promoting TH2 Skewing. Anesthesiology. 2016;124:908-22 pubmed publisher
  24. Liu L, Sommermeyer D, Cabanov A, Kosasih P, Hill T, Riddell S. Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol. 2016;34:430-4 pubmed publisher
  25. Roan F, Stoklasek T, Whalen E, Molitor J, Bluestone J, Buckner J, et al. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016;196:2051-2062 pubmed publisher
  26. Jutz S, Leitner J, Schmetterer K, Doel Perez I, Majdic O, Grabmeier Pfistershammer K, et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J Immunol Methods. 2016;430:10-20 pubmed publisher
  27. Barzilai S, Blecher Gonen R, Barnett Itzhaki Z, Zauberman A, Lebel Haziv Y, Amit I, et al. M-sec regulates polarized secretion of inflammatory endothelial chemokines and facilitates CCL2-mediated lymphocyte transendothelial migration. J Leukoc Biol. 2016;99:1045-55 pubmed publisher
  28. Frederiksen J, Buggert M, Noyan K, Nowak P, Sönnerborg A, Lund O, et al. Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection. PLoS ONE. 2015;10:e0137635 pubmed publisher
  29. Inglis H, Danesh A, Shah A, Lacroix J, Spinella P, Norris P. Techniques to improve detection and analysis of extracellular vesicles using flow cytometry. Cytometry A. 2015;87:1052-63 pubmed publisher
  30. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell L, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692 pubmed publisher
  31. Lin M, Yuan Y, Xu J, Cai X, Liu S, Niu L, et al. Safety and efficacy study of nasopharyngeal cancer stem cell vaccine. Immunol Lett. 2015;165:26-31 pubmed publisher
  32. Li J, Jie H, Lei Y, Gildener Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-518 pubmed publisher
  33. Lugassy J, Corso J, Beach D, Petrik T, Oellerich T, Urlaub H, et al. Modulation of TCR responsiveness by the Grb2-family adaptor, Gads. Cell Signal. 2015;27:125-34 pubmed publisher
  34. Valentin A, McKinnon K, Li J, Rosati M, Kulkarni V, Pilkington G, et al. Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clin Immunol. 2014;155:91-107 pubmed publisher
  35. Steiner S, Daniel C, Fischer A, Atreya I, Hirschmann S, Waldner M, et al. Cyclosporine A regulates pro-inflammatory cytokine production in ulcerative colitis. Arch Immunol Ther Exp (Warsz). 2015;63:53-63 pubmed publisher
  36. Frencher J, Shen H, Yan L, Wilson J, Freitag N, Rizzo A, et al. HMBPP-deficient Listeria mutant immunization alters pulmonary/systemic responses, effector functions, and memory polarization of Vγ2Vδ2 T cells. J Leukoc Biol. 2014;96:957-67 pubmed publisher
  37. Weist B, Schmueck M, Fuehrer H, Sattler A, Reinke P, Babel N. The role of CD4(+) T cells in BKV-specific T cell immunity. Med Microbiol Immunol. 2014;203:395-408 pubmed publisher
  38. Kulkarni V, Valentin A, Rosati M, Alicea C, Singh A, Jalah R, et al. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. PLoS ONE. 2014;9:e86254 pubmed publisher